Gene

FGFR1

fibroblast growth factor receptor 1

Explore in graph →CI-GENE-00001922HGNC:3688 ENSG00000077782 NCBI 2260 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (81)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 51–81 of 81 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR1 Expression5
Infigratinib	Head and Neck Squamous Cell Carcinoma	Predictive	D	Supports Sensitivity Response	3	accepted

Cohorts

Alteration frequency by cohort (94)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved94 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, JCO Precis Oncol 2022) crc_dd_2022	Colorectal Adenocarcinoma	Ssm	5

Literature

Linked publications (42)

25 per page, newest first.

pubmedPublishedShowing 26–42 of 42 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification.
· J Natl Compr Canc Netw · 2017 · PMID 29223982 · validated civic_curation pubmed
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
· Cancer Discov · 2014 · PMID 24302556 · validated civic_curation pubmed
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
· Sci Transl Med · 2010 · PMID 21160078 · validated civic_curation pubmed
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
· Mol Cancer Ther · 2011 · PMID 21482694 · validated

FGFR1 Internal Duplication2
(diagnostic)	Childhood Low Grade Glioma	Diagnostic	B	Supports Positive	4	accepted	EID7203 This GWAS study identified a structural variant of FGFR1. Duplication of the tyrosine kinase domain (TKD) of FGFR1 was found in 11 of 149 patients (13/151 tumor samples, including 2 recurrent tumors, … (full text at CIViC) PMID 23583981 · Zhang et al., 2013 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID13051 This GWAS study identified a structural variant of FGFR1. Duplication of the tyrosine kinase domain (TKD) of FGFR1 was found in 11 of 149 patients (13/151 tumor samples, including 2 recurrent tumors, … (full text at CIViC) PMID 23583981 · Zhang et al., 2013 · Open in CIViC	civic

FGFR1 Internal Duplication2

(diagnostic)

Childhood Low Grade Glioma

Diagnostic

Supports Positive

accepted

EID7203

This GWAS study identified a structural variant of FGFR1. Duplication of the tyrosine kinase domain (TKD) of FGFR1 was found in 11 of 149 patients (13/151 tumor samples, including 2 recurrent tumors, … (full text at CIViC)

PMID 23583981 · Zhang et al., 2013 · Open in CIViC

FGFR1 Overexpression3
(prognostic)	Bladder Urothelial Carcinoma	Prognostic	D	Supports Poor Outcome	4	submitted	EID9582 Two types of UC cell lines were compared in this study. T24 and J82 which are mesenchymal subtype and overexpress FGFR1, and RT-4 and UMUC-14, epithelial subtype which do not express FGFR1. T24 and J8… (full text at CIViC) PMID 30326563 · Kim et al., 2018 · Open in CIViC	civic
Fexagratinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID7952 Study of FGFR1 inhibitor AZD4547 in NSCLC xenograft models. FGFR1-amplified models that overexpress FGFR1 (detected by IHC) were strongly inhibited by 25mg/kg AZH4547 (P≤0.0001). Another FGFR1-ampli… (full text at CIViC) PMID 23082000 · Zhang et al., 2012 · Open in CIViC	civic
Docetaxel + RogaratinibCombination	Malignant Lung Neoplasm	Predictive	D	Supports Sensitivity Response	4	submitted	EID7831 Rogaratinib (BAY 1163877) was tested in cell line- and patient-derived models of lung cancer. DMS‐114 models, which have FGFR1 amplification and overexpression, had significantly decreased tumor volu… (full text at CIViC) PMID 30807645 · Grünewald et al., 2019 · Open in CIViC	civic

FGFR1 V561M2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID7512 In an in vitro kinase study, the recombinant FGFR1 V561M mutant kinase demonstrated resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 87 and 41) when compared to wild ty… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	submitted	EID7513 In an in vitro kinase study, the recombinant FGFR1 V561M mutant kinase demonstrated resistance to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 100 and 64) when compared to wild t… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC	civic

FGFR1 Fusion4
(diagnostic)	Chronic Myelomonocytic Leukemia	Diagnostic	A	Supports Negative	5	accepted	EID1427 The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusi… (full text at CIViC) PMID 27069254 · Arber et al., 2016 · Open in CIViC	civic
〃	Hematopoietic and Lymphoid Cell NeoplasmALIAS	Diagnostic	A	Supports Positive	5	accepted	EID1435 The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated wit… (full text at CIViC) PMID 27069254 · Arber et al., 2016 · Open in CIViC	civic
Sorafenib + SunitinibSubstitutes	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7375 In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 · Open in CIViC	civic
Sunitinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	rejected	EID7376 In a preclinical trial, KG1 AML cell lines with the FGFR1OP2-FGFR1 fusion mutation were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more e… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 · Open in CIViC	civic

FGFR1 Fusion + FGFR1 Fusion + FGFR1 Translocation + FGFR1 Fusion + FGFR1 Fusion3
Pemigatinib	Myeloid Neoplasm	Predictive	A	Supports Sensitivity Response	3	accepted	EID11324 In this phase 2, multicenter trial, 41 patients were enrolled who had myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Patients (pts) may present with… (full text at CIViC) Open in CIViC	civic
〃	Lymphoid Leukemia	Predictive	A	Supports Sensitivity Response	3	submitted	EID12241 In this phase 2, multicenter trial, 41 patients were enrolled who had myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Patients (pts) may present with… (full text at CIViC) Open in CIViC	civic
〃	Lymphoma	Predictive	A	Supports Sensitivity Response	3	submitted	EID12242 In this phase 2, multicenter trial, 41 patients were enrolled who had myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Patients (pts) may present with… (full text at CIViC) Open in CIViC	civic

FGFR1 N546K4
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	5	submitted	EID11023 FGFR1 N546K mutation affects the conformational dynamics of the tyrosine kinase domain, resulting in gain-of-function and ligand-independent constitutive activation. In vitro data show that FGFR1 N546… (full text at CIViC) PMID 35488346 · Cimmino et al., 2022 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11649 FGFR1, FGFR2, FGFR3 and FGFR4 variants found in human cancer were introduced into NIH3T3 cells and assessed for transformation and proliferation in an integrated qualitative assessment of focus format… (full text at CIViC) PMID 34272467 · Nakamura et al., 2021 · Open in CIViC	civic
Pemigatinib	Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID10325 Case report of a 32-year old male patient with pilocytic astrocytoma. Genomic profiling (FoundationOne) revealed a FGFR1 N546K mutation. The patient was enrolled in a phase I/II trial of pemigatinib a… (full text at CIViC) PMID 35507888 · Capone et al., 2022 · Open in CIViC	civic
Ponatinib	Bone Ewing SarcomaALIAS	Predictive	E	Supports Sensitivity Response	2	accepted	EID1246 116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis,… (full text at CIViC) PMID 26179511 · Agelopoulos et al., 2015 · Open in CIViC	civic